| Thursday, July 27, 2017 Will Mystic make it? That’s been the pressing question for AstraZeneca for months as the lung cancer trial proceeded. Answer: It didn’t, at least not yet. And it’s not just AZ's rep riding on that news, because Mystic was seen as a scrying glass of sorts. It would foretell which cancer cocktails would dominate over the next few years. | 
